Advanced Therapies Europe

The programme spans the priorities shaping cell and gene therapy and ATMP commercialisation—from clinical and regulatory planning through to manufacturing strategy, market access and patient involvement—bringing senior decision-makers together in a deliberately “intimate” format designed to maximise meaningful connections.

Who the audience is and how many attend

Audience

• Cell and gene therapy and regenerative medicine developers (biotech and pharma)
• Manufacturing and CMC leaders (including CDMOs and enabling technology partners)
• Investors and strategic partners active in advanced therapies
• Regulators, market access and commercial strategy stakeholders
• Solution providers supporting development, scale-up and commercial delivery

Scale

• Attendees: 500 (maximum capacity)
• Countries represented: 35+
• Speakers: 110+
• Therapeutic developers & pharma represented: 170+

What to expect

• A highly curated, senior audience with an emphasis on quality meetings over mass attendance
• Structured 1:1 partnering to set up targeted conversations before and during the event
• Strategy-led sessions covering clinical development, regulation, manufacturing, commercialisation and access
• Strong investor and dealmaking presence, with networking designed to move partnerships forward
• A concentrated three-day format in central Barcelona, suited to high-density meetings and collaboration